Answers are grounded in this paper and cite their sources.
Clinical commentary provides decision-making guidance for hydroxychloroquine use in COVID-19 and rheumatologic disorders, highlighting implications for chronic disease management.
Two medications often used for treatment of immune-mediated conditions, hydroxychloroquine and chloroquine, have recently attracted widespread interest as potential therapies for coronavirus disease 2019. The authors of this commentary provide guidance for clinical decision making for patients with coronavirus disease 2019 as well as for patients with rheumatologic conditions, such as systemic lupus erythematosus and rheumatoid arthritis
No takes yet. Share an insight, caveat, or question.
Yazdany et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: